Vensica's Achievements:
- The Vibe system: A needle-less delivery system utilizing the power of therapeutic ultrasound
- Botulinum Toxin A, in-licensed
- A simple and quick procedure for physicians
- Minimal pain and no anesthesia for patients
- Reduces risks and superior patient satisfaction
We first target Overactive Bladder
The Need
Our Solution
Our Solution
Botulinum Toxin A is highly efficacious in several bladder indications, including Overactive Bladder, Neurogenic Bladder, and Painful Bladder Syndrome. However, the toxin is currently injected into the bladder wall in an invasive procedure that involves side effects, pain and anesthesia.
Bladder cancer: in addition to toxin delivery, Vensica is also working to improve bladder cancer treatment with its proprietary platform.
Our Solution
Our Solution
Our Solution
Vensica developed a proprietary minimally invasive, needle-free device to deliver botulinum toxin A to the bladder. Vensica’s procedure is very simple and quick both for the urologist and the patient.
No needles, no anesthesia, and no cystoscopy required.
The Market
Our Solution
The Market
Overactive Bladder: Over 4 million patients fail oral medication treatment and seek a non-invasive solution to their illness.
Neurogenic Bladder: Over 1.5 million patients do not respond positively to oral medication treatment and seek a non-invasive solution to their illness.
Painful Bladder Syndrome: No effective treatment available for the 2 million patients in the USA.
Our Company
Vensica is a clinical stage biopharmaceutical company, founded in 2014 by Avner Geva to improve incontinence and bladder cancer treatments.
Since then the company has expanded with the recruitment of a team of world-leading urology experts, the signing of agreements with global companies, and the completion of a very successful clinical pilot trial.
The Team- Senior management
Avner Geva. CEO
Dr. Nissim Darvish. Chairman of the Board
Dr. Nissim Darvish. Chairman of the Board
10 years of experience in the life sciences industry. Yale Bsc (Biology), Technion MSc (Biomedical Engineering).
Dr. Nissim Darvish. Chairman of the Board
Dr. Nissim Darvish. Chairman of the Board
Dr. Nissim Darvish. Chairman of the Board
Senior manager, Oribmed Israel. Led number of companies to successful exits.
Avi Eftel. VP R&D
Dr. Nissim Darvish. Chairman of the Board
Avi Eftel. VP R&D
Extensive experience in leading start ups from inception to go-to-market. Technion MSc, System Engineering.